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Free and protein-bound tryptophan in serum of untreated patients with
chronic renal failure. In fasting sera from 46 untreated patients with
chronic renal failure and in 22 normal subjects, non-protein-bound
tryptophan, F, was separated by pH-controlled equilibrium dialysis.
Total tryptophan, T, and F were measured by HPLC. Results in
patients were related to gender, severity of chronic renal failure (as
measured by radioisotopic glomerular filtration rate), protein intake (as
measured by 24-hr urinary urea N excretion), and protein nutrition (as
measured by serum concentrations of albumin and transferrin). T was
subnormal in 59% of the patients. In seven hypoalbuminemic patients,
FIT was markedly increased (approaching unity) but F was normal. In
39 non-hypoalbuminemic patients, F was again normal but FIT was
often increased at glomerular filtration rates below 30 ml/min/3 m2 of
height2, especially in females. T was significantly correlated with
estimated protein intake (r 0.54, P = 0.0004), even though neither F
nor serum protein levels were correlated with it. We conclude that the
serum level of free tryptophan is well-maintained in chronic renal
failure, being uninfluenced by severity of renal insufficiency, voluntary
protein intake, or serum protein concentrations. On the other hand,
protein-bound tryptophan varies with protein intake, decreases mark-
edly in hypoalbuminemic patients, and also decreases in many non-
hypoalbuminemic patients (especially females) when the glomerular
filtration rate falls below approximately 30 ml/minl3 m2 of height2.
Tryptophan, unlike other amino acids in plasma, is largely
protein-bound. Assessment of the effective circulating concen-
tration of tryptophan therefore requires the determination of
non-protein-bound tryptophan.
In chronic renal failure, total serum or plasma tryptophan is
generally reduced owing to displacement of protein-bound
tryptophan by other ligands that accumulate [1—5]. Other as-
pects of tryptophan levels in chronic renal failure are unclear.
For example, free (that is, non-protein-bound) tryptophan in
patients with uremia is reported to be high [3, 4, 6], normal [7],
or low [8]. In cerebrospinal fluid of pre-dialysis patients,
tryptophan is increased [7, 9]. In muscle of patients on contin-
uous peritoneal dialysis, tryptophan levels may be high even
though plasma free tryptophan is low, according to a prelimi-
nary report [10].
In chronically uremic rats, total plasma tryptophan is also
low [11—14] but free tryptophan is high [13, 14], especially when
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dietary protein is restricted [10]. Tryptophanuria is prominent
[111. Brain levels of indoles may be high.
Many indolic metabolites accumulate in uremic plasma [4—6,
15—19]. Some are known carcinogens [15], and others have
major neuropsychiatric effects [20]. Until recently, studies of
the neuropsychiatric effects of tryptophan and its metabolites
focused principally on the 5-hydroxytryptamine pathway. More
recently, metabolites in the kynurenine pathway, which ac-
counts for 95% of tryptophan catabolism [21], have attracted
attention. Quinolinic acid, for example, is a potent neurotoxin,
the formation of which depends on tryptophan intake. Involve-
ment of these metabolites in many psychiatric disorders has
been postulated [22].
The possibility that tryptophan may play a role in the
progression of chronic renal failure is suggested by the obser-
vation that tryptophan radicals are readily generated by one-
electron oxidation [23, 241. However, tryptophan and some of
its metabolites are effective antioxidants [25]. The importance
of oxygen free radicals in the progression of renal injury has
recently been stressed [26, 27]. We have reported that serum
free tryptophan level is significantly correlated with rate of
progression of chronic renal failure [28], that is, higher levels
are associated with faster progression, as measured by rate of
decline of glomerular filtration rate.
The purpose of the present study was to assess free and total
tryptophan levels in untreated pre-dialysis patients.
Methods
Fasting serum (or, in preliminary studies, plasma) was ob-
tained from 46 patients with chronic renal failure and 22 normal
subjects. In patients, but not in normal subjects, whole blood
was also obtained, chilled in ice, and pH was measured at 250
within 30 minutes.
Determination of free and bound tryptophan in plasma or
serum
The following method was modified from Rocehi et al [29].
Venous blood was drawn with minimal stasis into a 5 or 10 ml
heparinized syringe, which was immediately placed in ice.
Within one hour pH was measured at room temperature.
Another tube of blood was drawn and allowed to clot.
Equilibrium dialysate was prepared as follows: 0.3 ml of 6%
dextran in 0.9% NaCI, adjusted to pH 7.4, was placed in a
Visking tube 8/32 cellulose dialysis bag. The bag was immersed
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in 3 ml plasma or serum which had been readjusted to the
original blood pH, and covered with mineral oil. Dialysis was
continued overnight in the dark. For total tryptophan, 1 ml of
plasma or serum was mixed with 0.2 ml of 30% trichloroacetic
acid and centrifuged at 2000 g for five minutes. The supernatant
was filtered through 0.45 m Millipore filter (HAWP) and stored
at 4°C. Tryptophan was measured in dialysate and in protein-
free supernatant of plasma or serum as follows. A Beckman
Model 332 liquid chromatograph equipped with a C-18 Ultra-
sphere OCS S column, 250 mm x 4.6 mm, was used. Optical
density at 278 nm was recorded and integrated. The mobile
phase was 0.02 M sodium phosphate buffer, pH 5.9:methanol
(HPLC-grade), 85:15. Flow rate was 1.2 mI/mm. Sample size
was 20 jsl. Tryptophan emerged at 7 to 9 minutes. Results were
calculated from peak height, not area, using a standard curve.
This was done because indoxyl sulfate was found to emerge less
than one minute later. In order to determine whether the
presence of indoxyl sulfate in these samples increased the
height of the tryptophan peak, samples from 14 patients were
rerun using a mobile phase consisting of acetic acid 0.2 M:iso-
propanol:tetrahydrofuran, 84:10:6, adjusted to pH 6.4 with
triethylamine [30]. In this system, tryptophan emerged at 3.9
minutes and indoxyl sulfate emerged at 6.0 minutes. Trypto-
phan concentrations estimated by this alternative method were
14 4% (sEM) higher; indoxyl sulfate concentrations are to be
reported elsewhere. Thus, no substantial error was introduced
by the presence of indoxyl sulfate.
In order to determine whether other compounds coelute with
tryptophan, samples from 10 of these patients were incubated
with tryptophanase (Sigma Chemicals) for 10 minutes at 37° in
the presence of pyridoxal phosphate using phosphate buffer pH
8.3 [31]. The tryptophan peak disappeared (indoxyl sulfate is
also destroyed by this enzyme).
Other observations on this method
We have found that: (1) recovery of tryptophan added to
normal or uremic serum averages 98 1% (sEM) (N = 8); (2)
protein binding is pH-dependent, particularly in the acid range
(Fig. 1); (3) free tryptophan is stable at 4°C for at least two
weeks in plasma or serum stored at 4°C; (4) heparinized plasma
contains 3 1 (suM) % less tryptophan per unit volume than
serum (this is probably a dilutional effect); (5) free tryptophan is
9 3 (sEM) % higher in plasma than in serum; thus, protein-
binding is only slightly reduced by heparin, contrary to Stefa-
nini and Biggio [32] but in confirmation of Bauman and Perry
[33].
Determination of glomerular filtration rate in patients
Following an oral water load of 10 to 15 mI/kg, 100 Ci of
99mTc.,labeled diethylenetriamine-pentaacetic acid (DTPA) was
injected i.v. Beginning one hour later, three timed urine collec-
tions of 30 to 40 minutes with blood samples at the beginning
and end of each collection were obtained. Urinary clearance of
the isotope was calculated for each period, averaged, and
expressed per 3 m2 of height2 (because average normal height2
is approximately 3 m2). Height rather than surface area was
used as a referent because it does not change, whereas weight
does, leading to misleading inferences in some patients [28].
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Fig. 1. pH dependence of protein-binding of trypophan. A pooled
sample of normal serum was dialyzed repeatedly, after modifying its pH
by addition of Na2HPO4 or NaH2PO4.
Estimation of protein intake in patients
Twenty-four hour urinary excretion rate of urea N (UNA)
was measured. Protein intake, in g/day, was estimated as 6.25
(UNA + 0.031 wt), where wt is weight in kg [34]. These
calculations are based on the assumptions that these untreated
patients were in N balance and had unchanging serum urea N
concentration.
Other measurements in patients were performed in the Clin-
ical Chemistry Laboratory.
Results
Hypoalbuminemic patients
Seven of 46 patients exhibited hypoalbuminemia (serum
albumin  3.4 g/dl). Their data were considered separately and
are displayed in detail in Table 1, in order of increasing serum
albumin concentration. Proteinuria in this group averaged 9
g/day. Serum transferrin was subnormal in five. Mean free
tryptophan level, F, 11.8 4.4 tLM, was not different from
normal subjects (Table 2), but total tryptophan, T, and protein-
bound tryptophan were greatly reduced, In the most severely
hypoalbuminemic patient (#71), the ratio, F/T, of free to total
tryptophan, 1.07, was the ratio to be expected if protein-binding
were absent (because serum is approximately 93% water). In all
seven, protein-bound tryptophan, B, calculated as B = (1.07 T)
.
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Table 1. Observations in seven hypoalbuminemic patients
Pt #
Age
years Sex Dx
EPI U0,
g/day
GFR
mi/mm
Mb
g/dl
Trans Chol TG
Tryptophan
Total
/M
Free
M Free/totalmg/di
71 39 F G 73 24 28 2.3 185 443 153 18.5 19.9 1.07
118 64 M H 40 5 4 2.5 169 292 311 14.3 6.8 0.48
44 31 M D 32 5 9 2.6 162 201 62 21.4 9.7 0.45
46 80 F G 39 6 31 3.1 234 384 177 25.3 14.3 0.56
61 37 M D 93 5 41 3.1 223 181 55 29.6 12.8 0.45
60 72 F F 44 3 26 3.2 183 273 148 15.2 11.5 0.76
65 37 M D 51 14 20 3.2 214 340 100 16.1 7.8 0.49
Mean 45 53 9 23 2.9 196 302 144 20.0 11.8 0.61
5D 26 22 8 13 0.4 28 94 87 5.7 4.4 0.23
Abbreviations are: EPI, estimated protein intake; U01, proteinuria; GFR, glomerular filtration rate (corrected to 3 m2 of height2); Aib, serum
albumin; Trans, serum transferrin; Chol, serum cholesterol; TG, serum triglycerides; Dx, diagnosis—D, insulin-dependent diabetes; F, fibrillary
nephritis; 0, glomerulonephritis; H, arteriolar nephrosclerosis.
N Total trp, M Free trp, /LM Free/total
Females
Normals
Patients
P
Males
Normals
Patients
P
10
13
12
26
50.4 8.2
30.3 6.0
0.0001
50.5 6.4
37.6 7.5
0.0001
11.0 3.2
10.4 2.5
NS
10.6 3.0
9.2 2.0
NS
0.21 0.04
0.36 0.12
0.0012
0.21 0.06
0.25 0.06
0.055
Data are means SD.
—F, was more reduced than was serum albumin concentration.
The explanation for this apparent reduction in the aflinity of
albumin for binding of tryptophan is not apparent, although
some reduction is attributable to renal failure and protein
restriction (see below).
Non-hypoalbuminemic patients
As shown in Table 2, T was considerably reduced (especially
in females), compared to normal subjects. F, however, was
normal. T was below the 95% confidence limit of normal (34
tM) in half of these non-hypoalbuminemic patients. Thus the
ratio FIT was increased, particularly in females.
Within this group of 39 patients we sought to determine which
factors were important determinants of F and T. Age was not a
significant predictor, nor was serum level of transferrin or
albumin (although, as indicated previously, albumin is a major
determinant when hypoalbuminemic patients are also consid-
ered). As shown in Table 3 and Figure 2, protein-binding was
significantly correlated (negatively) with glomerular filtration
rate. T was positively correlated with estimated protein intake
(Fig. 3), which varied from 25 to 114 g/day (mean 63 22 SD
g/day), but F was not (Fig. 4).
When stepwise multiple regression was used to determine
which of the measured independent variables were predictors of
B, we found that estimated protein intake, glomerular filtration
rate and gender were all significant predictors. The combined
regression equation is:
Table 3. Correlation coefficients between measured parameters in 39
non-hypoalbuminemic patients
GFR AIb Trans EPI
Total trp
Free trp
Free/total
o.35 NS
NS
NS
NS
NS
NS
0.54e
NS
NS
GFR — NS NS NS
Alb — NS NS
Trans — NS
Abbreviations are: trp, tryptophan; GFR, glomerular filtration rate;
Aib, serum albumin; Trans, serum transferrin; EPI, estimated protein
intake.
a P < 0.05b P < 0.02
P = 0.0004
0.6
B = 1.0 3.4 + (0.124 0.054) EPI + (0.163 0.054) GFR +
(5.6 2.5) Gender, where Gender = 0 for females and 1 for
males.
This equation predicts 48% (=r2)of the observed variation in B
in these 39 non-hypoalbuminemic patients.
Table 2. Free and total tryptophan in serum of non-hypoalbuminemic
chronic renal failure patients, compared with normal subjects
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Fig. 2. Ratio of free to total tryptophan in serum of 39 non-hypoalbu-
minemic patients as a function of glomerular filtration rate.
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Table 4. Mean free and total tryptophan in normal human plasma or
serum, smol/liter, according to various workers
Method Total Free Free/total Reference
Ultrafiltration 68
68
70
57
56
71
68
52
68
5
9
10
2
12
7
4
8
18
0.07
0.14
0.12
0.04
0.21
0.10
0.07
0.15
0.26
48
33
8
49
50, 51
6
4
7
52
Equilibrium dialysis 84
66
51
69
42
66
50
9
6
12
17
9
8
11
0.12
0.09
0.24
0.24
0.22
0.12
0.21
53
54
10
55
29
30
This study
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Estimated protein intake, 9/day
Fig. 3. Total serum tryptophan as a function of estimated protein
intake in the same samples as in Figure 2. Linear regression shown.
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Powell [35]. In the present method, the ratio of volume of serum
to volume of dialysate is 10:1, so that little change in this
equilibrium is expected.
In renal failure, the importance of pH control increases, since
acidosis is often present. None of our patients had severe
acidosis. Nevertheless, we felt it was important to maintain
serum pH at its in vivo value during dialysis.
Comparison of our findings in chronic renal failure patients
• with the previous studies that we have identified [3, 4, 6—8]
___________________________________
shows that our results are more similar to those of Sullivan et a!
[7] than to the others. Sullivan et al [7] and Lagana et al [6] did
not control pH during ultrafiltration. Sullivan et at [7] corrected
• measured values of ultrafiltrate tryptophan for measured pH of
stored plasma using a standard curve. Saito et al [4] adjusted
serum pH to 7.4 before ultrafiltration but did not measure pH
after ultrafiltration. These patients were all on dialysis, in
_____
contrast to our study and that of Sullivan et al [7] and Cernacek
0 20 40 60 80 100 1 k et a! [8]. Lagana et al [6] do not state whether or not theirpatients were on dialysis.
Tryptophan concentration may be important in chronic renal
failure for several reasons: (1) it is an essential amino acid that
is not only required for protein synthesis, but also is believed to
play a unique role in the regulation of protein turnover [21,
36—41]; (2) supplements to very low protein diets currently
under study in the treatment of chronic renal failure generally
contain all of the essential amino acids as such or as their
keto-analogues, with the exception of tryptophan, which may
be low or absent; (3) administration of tryptophan may cause a
Estimated protein intake, 9/day
Fig. 4. Free tryptophan in serum as a function of estimated protein
intake in the same samples as in Figure 2. Linear regression shown.
Discussion
We have identified fifteen previous studies in which mean
values for T and F in normal human plasma or serum are
reported (Table 4). Our results in normal subjects are compa-
rable to these previous data.
The two methods used for measuring F, ultrafiltration and
equilibrium dialysis, both have their disadvantages. pH control
during ultrafiltration is difficult to achieve, even when it is
carried out in a C02-containing atmosphere. The progressive
rise in plasma or serum pH that usually occurs during ultrafil-
tration in air is probably responsible for some of the lower
values for free/total tryptophan that have been reported (Table
4). Equilibrium dialysis necessarily disturbs the equilibrium
between free and bound tryptophan. The extent of the error so
introduced has been considered by Chadwick, Phipps and
severe disorder known as the cosinophilia-myalgia syndrome,
which may or may not be caused by a specific contaminant [42];
(4) as noted in the introduction, tryptophan metabolites exert
neuropsychiatric effects; (5) in a retrospective analysis, F was
significantly correlated with rate of decline of glomerular filtra-
tion rate [28].
The present study was limited to untreated patients and
therefore sheds no light on points (2), (3), or (5). However, our
observation that F is well-maintained in these patients suggests
neither point (1) nor point (4) are sources of concern.
The absence of any dependence of F on protein intake over a
fivefold range (Fig. 4) is surprising, since fasting concentrations
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of other essential amino acids are generally strongly dependent
on the level of protein intake [43—46]. These findings suggest
that metabolic degradation of tryptophan, most of which occurs
via the kynurenine pathway [21], may be regulated differently in
response to variations in protein intake than are the degradative
pathways of other essential amino acids, most of which involve
oxidative enzymes.
The strong dependence of T on protein intake (Fig. 3) is also
surprising, particularly because there was no correlation be-
tween serum albumin concentration and protein intake (Table
3). Thus, the apparent affinity of albumin for binding of trypto-
phan increases with protein intake, and conversely, if interfer-
ence by organic acids (including free fatty acids) in the albumin-
binding of tryptophan is invoked to explain these results, the
responsible organic acids would necessarily be present at higher
levels in low protein diets. This seems implausible. However, a
change in as yet unidentified plasma constituents that increase
or decrease the affinity of albumin for tryptophan may explain
these findings. It would be of interest to vary protein intake and
determine whether bound tryptophan changes.
The diminution in protein-binding of tryptophan at low levels
of GFR (Fig. 2) is almost certainly attributable to competition
from organic acids, derived from metabolism and retained
owing to impaired tubular secretion, as has been pointed out
previously [1—5].
In hypoalbuminemic subjects (Table I), a further decrease in
albumin affinity for tryptophan is apparent, not explained by
their protein intake or severity of renal failure. Conceivably,
hyperlipidemia, which was present in most of these subjects
(Table 1) may be responsible. Cholesterol level was correlated
with FIT in this small series (r = 0.68) but triglyceride level was
not. We did not measure levels of free fatty acids, which may be
particularly effective in competing for binding of tryptophan
[47].
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